Declining Epstein-Barr Virus Antibody Prevalence in College Freshmen Strengthens the Rationale for a Prophylactic EBV Vaccine
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Population
2.2. EBV Antibody Assay
2.3. Statistical Analysis
3. Results
3.1. EBV VCA IgG Antibody Kit Comparison
3.2. EBV Antibody Prevalence
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- De-The, G.; Day, N.E.; Geser, A.; Lavoue, M.F.; Ho, J.H.; Simons, M.J.; Sohier, R.; Tukei, P.; Vonka, V.; Zavadova, H. Sero-epidemiology of the Epstein-Barr virus: Preliminary analysis of an international study—A review. IARC Sci. Publ. 1975, 11, 3–16. [Google Scholar]
- Lanz, T.V.; Brewer, R.C.; Ho, P.P.; Moon, J.S.; Jude, K.M.; Fernandez, D.; Fernandes, R.A.; Gomez, A.M.; Nadj, G.S.; Bartley, C.M.; et al. Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM. Nature 2022, 603, 321–327. [Google Scholar] [CrossRef] [PubMed]
- Bjornevik, K.; Cortese, M.; Healy, B.C.; Kuhle, J.; Mina, M.J.; Leng, Y.; Elledge, S.J.; Niebuhr, D.W.; Scher, A.I.; Munger, K.L.; et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science 2022, 375, 296–301. [Google Scholar] [CrossRef] [PubMed]
- Balfour, H.H., Jr.; Schmeling, D.O.; Grimm-Geris, J.M. The promise of a prophylactic Epstein-Barr virus vaccine. Pediatr. Res. 2020, 87, 345–352. [Google Scholar] [CrossRef] [PubMed]
- Sokal, E.M.; Hoppenbrouwers, K.; Vandermeulen, C.; Moutschen, M.; Leonard, P.; Moreels, A.; Haumont, M.; Bollen, A.; Smets, F.; Denis, M. Recombinant gp350 vaccine for infectious mononucleosis: A phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J. Infect. Dis. 2007, 196, 1749–1753. [Google Scholar] [CrossRef]
- Balfour, H.H., Jr.; Odumade, O.A.; Schmeling, D.O.; Mullan, B.D.; Ed, J.A.; Knight, J.A.; Vezina, H.E.; Thomas, W.; Hogquist, K.A. Behavioral, virologic, and immunologic factors associated with acquisition and severity of primary Epstein-Barr virus infection in university students. J. Infect. Dis. 2013, 207, 80–88. [Google Scholar] [CrossRef] [PubMed]
- Grimm, J.M.; Schmeling, D.O.; Dunmire, S.K.; Knight, J.A.; Mullan, B.D.; Ed, J.A.; Brundage, R.C.; Hogquist, K.A.; Balfour, H.H., Jr. Prospective studies of infectious mononucleosis in university students. Clin. Transl. Immunol. 2016, 5, e94. [Google Scholar] [CrossRef] [PubMed]
- Grimm-Geris, J.M.; Dunmire, S.K.; Duval, L.M.; Filtz, E.A.; Leuschen, H.J.; Schmeling, D.O.; Kulasingam, S.L.; Balfour, H.H., Jr. Screening for Epstein-Barr virus (EBV) infection status in university freshmen: Acceptability of a gingival swab method. Epidemiol. Infect. 2019, 147, e140. [Google Scholar] [CrossRef] [PubMed]
- Takeuchi, K.; Tanaka-Taya, K.; Kazuyama, Y.; Ito, Y.M.; Hashimoto, S.; Fukayama, M.; Mori, S. Prevalence of Epstein-Barr virus in Japan: Trends and future prediction. Pathol. Int. 2006, 56, 112–116. [Google Scholar] [CrossRef] [PubMed]
- Balfour, H.H., Jr.; Sifakis, F.; Sliman, J.A.; Knight, J.A.; Schmeling, D.O.; Thomas, W. Age-specific prevalence of Epstein-Barr virus infection among individuals aged 6-19 years in the United States and factors affecting its acquisition. J. Infect. Dis. 2013, 208, 1286–1293. [Google Scholar] [CrossRef]
- Fourcade, G.; Germi, R.; Guerber, F.; Lupo, J.; Baccard, M.; Seigneurin, A.; Semenova, T.; Morand, P.; Epaulard, O. Evolution of EBV seroprevalence and primary infection age in a French hospital and a city laboratory network, 2000–2016. PLoS ONE 2017, 12, e0175574. [Google Scholar] [CrossRef]
- Babiker, H.M.; Wiedenbeck, T.; Robetorye, R.S.; Acharya, U.; Wilansky, S.; Kusne, S. Acute systemic viral infection masquerading as an infiltrating lymphoma in an elderly patient: A case report and review of the literature. Case Rep. Med. 2013, 2013, 318358. [Google Scholar] [CrossRef] [PubMed]
- Choi, A.; Marcus, K.; Pohl, D.; Eyck, P.T.; Balfour, H.H., Jr.; Jackson, J.B. Epstein-Barr virus infection status among first year undergraduate university students. J. Am. Coll. Health 2022, 70, 22–25. [Google Scholar] [CrossRef] [PubMed]
Study Population | Class of 2010 | Class of 2011 | Class of 2016 | Class of 2021 | Class of 2025 |
---|---|---|---|---|---|
Month/Year Tested | September/October 2006 | September 2007 | September 2012 | September/October 2017 | November/December 2021 April 2022 |
No. of Participants | 267 | 279 | 279 | 221 | 150 |
Age Range in Years (median, mean) | 18–22 (18.6, 18.6) | 18–23 (18.6, 18.6) | 18–21 (18.6, 18.6) | 18–19 (18.7, 18.7) | 18–20 (18.0, 18.4) |
Antibody Positive Male | 59/99 (60%) | 70/121 (58%) | 78/167 (47%) | 47/85 (55%) | 21/41 (51%) |
Antibody Positive Female | 111/168 (66%) | 104/158 (66%) | 66/112 (59%) | 75/135 (56%) | 55/104 (53%) |
Antibody Positive Male & Female | 170/267 (64%) | 174/279 (62%) | 144/279 (52%) | 123/221 (56%) * | 78/150 (52%) ** |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Balfour, H.H., Jr.; Meirhaeghe, M.R.; Stancari, A.L.; Geris, J.M.; Condon, L.M.; Cederberg, L.E. Declining Epstein-Barr Virus Antibody Prevalence in College Freshmen Strengthens the Rationale for a Prophylactic EBV Vaccine. Vaccines 2022, 10, 1399. https://doi.org/10.3390/vaccines10091399
Balfour HH Jr., Meirhaeghe MR, Stancari AL, Geris JM, Condon LM, Cederberg LE. Declining Epstein-Barr Virus Antibody Prevalence in College Freshmen Strengthens the Rationale for a Prophylactic EBV Vaccine. Vaccines. 2022; 10(9):1399. https://doi.org/10.3390/vaccines10091399
Chicago/Turabian StyleBalfour, Henry H., Jr., Madeline R. Meirhaeghe, Arianna L. Stancari, Jennifer M. Geris, Lawrence M. Condon, and Laurel E. Cederberg. 2022. "Declining Epstein-Barr Virus Antibody Prevalence in College Freshmen Strengthens the Rationale for a Prophylactic EBV Vaccine" Vaccines 10, no. 9: 1399. https://doi.org/10.3390/vaccines10091399